Schroeder MA, Hari PN, Blithe A, Paranagama D, et al. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplant 2022 Apr 18. pii: 10.1038/s41409-022-01673.
PMID: 35437311